SENSIMED Triggerfish clinical outcomes to be presented at ARVO congress 2013
PRESS RELEASE - Sensimed AG, announced today that 10 scientific publications reporting outcomes of clinical studies investigating the use of SENSIMED Triggerfish® will be presented at ARVO 2013. The company developed the SENSIMED Triggerfish®, a revolutionary contact lens for the continuous recording of the 24-hour intraocular pressure (IOP) pattern to facilitate the management of glaucoma.
Sensimed to actively participate in the coming Glaucoma 360 Conference and at the American Glaucoma Society in the USA
PRESS RELEASE - Sensimed AG, announced today that the company will participate in two major glaucoma meetings taking place in San Francisco in February 2013. Sensimed is proud to present its breakthrough technology at the Glaucoma 360 New Horizons Forum being held on Friday, February 1st, 2013 at the Palace Hotel, in San Francisco.In addition, the company will present 4 scientific abstracts at the upcoming American Glaucoma Society (AGS) meeting from February 28th to March 3rd 2013 in San Francisco.
Sensimed AG receives a new reimbursement code in the USA for monitoring of intraocular pressure
PRESS RELEASE - Sensimed AG, announced today that the American Medical Association (AMA) has approved a new Current Procedural Terminology (CPT®) code for monitoring of IOP for 24 hours or longer.
Sensimed will be presenting at the HealthStartup Europe in London on December 12th, 2012.
PRESS RELEASE - The HealthStartup event with the theme on “health data integration”, will gather a select group of approximately 100 investors, entrepreneurs and healthcare decision makers. The mission of HealthStartup is to enhance synergy between start-up and investors by creating panel discussions with topic experts.
Sensimed AG Raises 17 Million CHF in Series C Financing
PRESS RELEASE - Sensimed AG announced today the first closing of its Series C financing round co-led by Wellington Partners, Agate Medical Investments and Vinci Capital/Renaissance PME. The first closing at CHF 17m was completed by current shareholders, the Sandoz Family Foundation, ELM Development, and successful entrepreneurs in the medical devices industry.
Sensimed will be presenting at the Ophthalmology Innovation Summit @ AAO in Chicago on November 8th, 2012
PRESS RELEASE - The Ophthalmology Innovation Summit Unites the Key Players and Industry Leaders in the Development of Ophthalmic Products, Drugs and Devices, including 700+ Innovators/Entrepreneurs, Clinicians, Venture Capitalists, Senior R&D and Biz Dev Execs from Private and Public Companies. The mission of OIS is to bring new technologies to market by facilitating information transfer, deal-flow, strategic partnerships and acquisitions.